Literature DB >> 21175974

Adriamycin nephropathy: a model of focal segmental glomerulosclerosis.

Vincent W S Lee1, David C H Harris.   

Abstract

Adriamycin nephropathy (AN) is a rodent model of chronic kidney disease that has been studied extensively and has enabled a greater understanding of the processes underlying the progression of chronic proteinuric renal disease. AN is characterized by podocyte injury followed by glomerulosclerosis, tubulointerstitial inflammation and fibrosis. Genetic studies have demonstrated a number of loci that alter both risk and severity of renal injury induced by Adriamycin. Adriamycin-induced renal injury has been shown in numerous studies to be modulated by both non-immune and immune factors, and has facilitated further study of mechanisms of tubulointerstitial injury. This review will outline the pharmacological behaviour of Adriamycin, and describe in detail the model of AN, including its key structural characteristics, genetic susceptibility and pathogenesis.
© 2011 The Authors. Nephrology © 2011 Asian Pacific Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175974     DOI: 10.1111/j.1440-1797.2010.01383.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  144 in total

1.  The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy.

Authors:  Changbin Li; Yan Ge; Lance Dworkin; Ai Peng; Rujun Gong
Journal:  J Pathol       Date:  2016-03-16       Impact factor: 7.996

2.  Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy.

Authors:  Mixuan Yi; Lei Zhang; Yu Liu; Man J Livingston; Jian-Kang Chen; N Stanley Nahman; Fuyou Liu; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2017-04-12

3.  Arrestin(g) podocyte injury with endothelin antagonism.

Authors:  Roderick J Tan; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 10.121

4.  A new mechanism for albuminuria-induced podocyte injury.

Authors:  Sandeep K Mallipattu; John C He
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

5.  Nephrin Preserves Podocyte Viability and Glomerular Structure and Function in Adult Kidneys.

Authors:  Xuezhu Li; Peter Y Chuang; Vivette D D'Agati; Yan Dai; Rabi Yacoub; Jia Fu; Jin Xu; Oltjon Taku; Prem K Premsrirut; Lawrence B Holzman; John Cijiang He
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

Review 6.  Recent advances of animal model of focal segmental glomerulosclerosis.

Authors:  Jae Won Yang; Anne Katrin Dettmar; Andreas Kronbichler; Heon Yung Gee; Moin Saleem; Seong Heon Kim; Jae Il Shin
Journal:  Clin Exp Nephrol       Date:  2018-03-20       Impact factor: 2.801

7.  Catalpol alleviates adriamycin-induced nephropathy by activating the SIRT1 signalling pathway in vivo and in vitro.

Authors:  Jiangnan Zhang; Ran Bi; Qiang Meng; Changyuan Wang; Xiaokui Huo; Zhihao Liu; Chong Wang; Pengyuan Sun; Huijun Sun; Xiaodong Ma; Jingjing Wu; Kexin Liu
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

8.  (Pro)renin receptor decoy peptide PRO20 protects against adriamycin-induced nephropathy by targeting the intrarenal renin-angiotensin system.

Authors:  Renfei Luo; Kevin Yang; Fei Wang; Chuanming Xu; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-31

9.  Podocyte-Specific Induction of Krüppel-Like Factor 15 Restores Differentiation Markers and Attenuates Kidney Injury in Proteinuric Kidney Disease.

Authors:  Yiqing Guo; Jesse Pace; Zhengzhe Li; Avi Ma'ayan; Zichen Wang; Monica P Revelo; Edward Chen; Xiangchen Gu; Ahmed Attalah; Yaqi Yang; Chelsea Estrada; Vincent W Yang; John C He; Sandeep K Mallipattu
Journal:  J Am Soc Nephrol       Date:  2018-08-24       Impact factor: 10.121

10.  Induction of retinol dehydrogenase 9 expression in podocytes attenuates kidney injury.

Authors:  Xuezhu Li; Yan Dai; Peter Y Chuang; John Cijiang He
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.